GlassScriptPhysician profile
Rodney Quinn
NPI 1881638591
$383.38
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $164 · 2021: $23.92.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $86.44 | 2020 | |
| Novartis Pharmaceuticals Corporation | $79.24 | 2019-2020 | |
| Emd Serono, INC. | $49.07 | 2019-2020 | |
| Allergan, INC. | $42.77 | 2019-2020 | |
| Pfizer INC. | $26.67 | 2019 | |
| Mdd US Operations, LLC | $24.54 | 2020 | |
| Abbvie INC. | $23.92 | 2021 | |
| Alnylam Pharmaceuticals INC. | $21.89 | 2019 | |
| Aprecia Pharmaceuticals, LLC | $15.02 | 2020 | |
| Livanova USA, INC. | $13.82 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodney Quinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.